IBD Clinical Trial Eligibility

Request edit access

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

The purpose of this research while administering Vedolizumab (Entyvio) is to test the short and long-term decrease or disappearance of symptoms associated with moderate to severely active Crohn’s Disease (CD) or Ulcerative Colitis (UC), understand the ease of switching Vedolizumab from intravenous to Vedolizumab subcutaneous, collect information on the reduction of impact on the physical and mental health.

Benefits

Study-related care from a gastroenterologist at no cost
Compensation for your time and participation
Reimbursement for study-related travel
Study medication provided at no cost

Location

Queens, New York

Duration

72 Weeks

After filling out this form, we will contact you shortly regarding the trial!

Full Name *

Email *

Phone Number *

Age *

Have you been diagnosed with moderate to severely active ulcerative colitis (UC) or Crohn's disease (CD)? *

Yes

Have you previously undergone treatment with corticosteroids or other therapies for your condition, and has your healthcare provider determined that these treatments are no longer effective or appropriate for you?Have you been diagnosed with moderate to severely active ulcerative colitis (UC) or Crohn's disease (CD)? *

Yes

Any questions/comments for us?

Submit

Clear form

Never submit passwords through Google Forms.

This form was created inside of IMIDeology.

Does this form look suspicious? Report

Forms